Skip to main content
SpringerLink
Log in

Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: The modulation of LDL size and subclasses in high-risk patients

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Increasing evidence suggests that the quality—rather than just the quantity—of low-density lipoproteins (LDLs) exerts a great influence on cardiovascular risk. LDLs comprise multiple subclasses with discrete size and density, and different physicochemical composition, metabolic behaviors, and atherogenicity. Individuals generally cluster into 2 broad subgroups. Most have a predominance of large LDLs, and some have a higher proportion of small particles. Small, dense LDLs are good predictors of cardiovascular events and progression of coronary artery disease. Their predominance has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. Several studies have shown that therapeutic modulation of LDL size and subclass is of great benefit in reducing the risk of cardiovascular events. This seems particularly true for statins and fibrates when they are administered to higher-risk patients, such as those with type 2 diabetes or vascular disease. Data reporting outcomes with the use of rosuvastatin, the latest statin molecule introduced to the market, and ezetimibe, a cholesterol absorption inhibitor, are promising.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Krauss RM. Dietary and genetic probes of atherogenic dyslipidemia.Arterioscler Thromb Vasc Biol. 2005; 25: 2265–2272.

    Article  PubMed  CAS  Google Scholar 

  2. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity.J Lipid Res. 2002; 43: 1363–1379.

    Article  PubMed  CAS  Google Scholar 

  3. Georgieva AM, van Greevenbroek MMJ, Krauss RM, et al. Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype.Arterioscler Thromb Vasc Biol. 2004; 24: 1–7.

    Article  Google Scholar 

  4. Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size?Int J Cardiol. 2006; 107: 147–151.

    Article  Google Scholar 

  5. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.Circulation. 2002; 106: 3143–3421.

    Google Scholar 

  6. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction.JAMA. 1988; 260: 1917–1921.

    Article  PubMed  CAS  Google Scholar 

  7. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment.QJM. 2006; 99: 1–14.

    Article  PubMed  CAS  Google Scholar 

  8. Sacks FM, Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal.J Clin Endocrinol Metab. 2003; 88: 4525–4532.

    Article  PubMed  CAS  Google Scholar 

  9. Rizzo M, Berneis K. The clinical relevance of low-density lipoproteins size modulation by statins.Cardiovasc Drugs Ther. 2006; 20: 205–217.

    Article  PubMed  CAS  Google Scholar 

  10. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles.Expert Opin Biol Ther. 2007; 7: 53–72.

    Article  PubMed  CAS  Google Scholar 

  11. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.Am J Cardiol. 2002; 90: 89–94.

    Article  PubMed  CAS  Google Scholar 

  12. Otvos JD, Shalaurova I, Freedman DS, Rosenson RS. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial.Atherosclerosis. 2002; 160: 41–48.

    Article  PubMed  CAS  Google Scholar 

  13. Rizzo M, Barbagallo CM, Pernice V, et al. Effects “beyond-cholesterol” of statins: simvastatin reduces the levels of atherogenic lipoproteins in patients with premature coronary artery disease.Nutr Metab Cardiovasc Dis. 2002; 12: 239.

    Google Scholar 

  14. Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.Coron Artery Dis. 1996; 7: 843–850.

    Article  PubMed  CAS  Google Scholar 

  15. Kazama H, Usui S, Okazaki M, Hosoi T, Ito H, Orimo H. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes.Diabetes Res Clin Pract. 2003; 59: 181–189.

    Article  PubMed  CAS  Google Scholar 

  16. Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.Prev Cardiol. 2003; 6: 179–188.

    Article  PubMed  CAS  Google Scholar 

  17. Winkler K, Abletshauser C, Hoffmann MM, et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action.J Clin Endocrinol Metab. 2002; 87: 5485–5490.

    Article  PubMed  CAS  Google Scholar 

  18. Freed MI, Ratner R, Marcovina SM, et al, for the Rosiglitazone Study 108 Investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.Am J Cardiol. 2002; 90: 947–952.

    Article  PubMed  CAS  Google Scholar 

  19. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.Metabolism. 2002; 51: 334–342.

    Article  PubMed  CAS  Google Scholar 

  20. Wägner AM, Jorba O, Bonet R, Ordóñez-Llanos J, Pérez A. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia.J Clin Endocrinol Metab. 2003; 88: 3212–3217.

    Article  PubMed  Google Scholar 

  21. Ikejiri A, Hirano T, Murayama S, et al. Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.Metabolism. 2004; 53: 1113–1117.

    Article  PubMed  CAS  Google Scholar 

  22. Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.Am J Cardiol. 2001; 87: 44–48.

    Article  PubMed  CAS  Google Scholar 

  23. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, et al, for the CARDS Investigators. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.Atherosclerosis. 2003; 167: 243–255.

    Article  PubMed  CAS  Google Scholar 

  24. Caslake MJ, Stewart G, Day SP, et al. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia.Atherosclerosis. 2003; 171: 245–253.

    Article  PubMed  CAS  Google Scholar 

  25. Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, Kuusi T, Taskinen MR. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.Diabetes Care. 1993; 16: 584–592.

    Article  PubMed  CAS  Google Scholar 

  26. O’Neal DN, O’Brien RC, Timmins KL, et al. Gemfibrozil treatment increases low-density lipoprotein particle size in type 2 diabetes mellitus but does not alter in vitro oxidizability.Diabet Med. 1998; 15: 870–877.

    Article  PubMed  CAS  Google Scholar 

  27. Superko HR, Berneis KK, Williams PT, Rizzo M, Wood PD. Gemfibrozil reduces small lowdensity lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.Am J Cardiol. 2005; 96: 1266–1272.

    Article  PubMed  CAS  Google Scholar 

  28. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.Circulation. 2006; 113: 1556–1563.

    Article  PubMed  CAS  Google Scholar 

  29. Kondo A, Morita H, Nakamura H, et al. Influence of fibrate treatment on malondialdehydemodified LDL concentration.Clin Chim Acta. 2004; 339: 97–103.

    Article  PubMed  CAS  Google Scholar 

  30. Hayashi K, Kurushima H, Kuga Y, et al. Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance.Cardiovasc Drugs Ther. 1998; 12: 3–12.

    Article  PubMed  CAS  Google Scholar 

  31. Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).J Am Coll Cardiol. 1998; 32: 1648–1656.

    Article  PubMed  CAS  Google Scholar 

  32. Ayaori M, Momiyama Y, Fayad ZA, et al. Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia.Atherosclerosis. 2006 Dec 29; [Epub ahead of print].

  33. Feher MD, Caslake M, Foxton J, Cox A, Packard CJ. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate.Diabetes Metab Res Rev. 1999; 15: 395–399.

    Article  PubMed  CAS  Google Scholar 

  34. Tan CE, Chew LS, Tai ES, et al. Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.Atherosclerosis. 2001; 154: 469–474.

    Article  PubMed  CAS  Google Scholar 

  35. Vakkilainen J, Steiner G, Ansquer JC, et al, for the DAIS Group. Relationships between lowdensity lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).Circulation. 2003; 107: 1733–1737.

    Article  PubMed  Google Scholar 

  36. Al-Shaer MH. The effects of ezetimibe on the LDL-cholesterol particle number.Cardiovasc Drugs Ther. 2004; 18: 327–328.

    Article  PubMed  CAS  Google Scholar 

  37. Geiss HC, Otto C, Parhofer KG. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.Metabolism. 2006; 55: 599–604.

    Article  PubMed  CAS  Google Scholar 

  38. Farnier M, Freeman MW, Macdonell G, et al, for the Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.Eur Heart J. 2005; 26: 897–905.

    Article  PubMed  CAS  Google Scholar 

  39. Grundy SM, Cleeman JI, Merz CNB, et al, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Circulation. 2004; 110: 227–239.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Medicine and Emerging Diseases, University of Palermo, Via del Vespro, 141, 90127, Palermo, Italy

    Manfredi Rizzo MD, PhD & Giovam Battista Rini MD

  2. Clinic for Endocrinology, Diabetes, and Clinical Nutrition, University Hospital, Zurich, Switzerland

    Kaspar Berneis MD

Authors
  1. Manfredi Rizzo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovam Battista Rini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kaspar Berneis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manfredi Rizzo MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rizzo, M., Rini, G.B. & Berneis, K. Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: The modulation of LDL size and subclasses in high-risk patients. Adv Therapy 24, 575–582 (2007). https://doi.org/10.1007/BF02848780

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02848780

Keywords

Search

Navigation